Promoter methylation of leukemia inhibitory factor receptor gene in colorectal carcinoma

International Journal of Oncology

Volumn 39, Issue 2, 2011, Pages 337-344

  Cho, Yong Gu ^a   Chang, Xiaofei ^a   Park, Il Seok ^b   Yamashita, Keishi ^c   Shao, Chunbo ^a   Ha, Patrick K ^a   Pai, Sarai ^a   Sidransky, David ^a   Kim, Myoung Sook ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b Hallym University   (South Korea)

^c KITASATO UNIVERSITY HOSPITAL   (Japan)

Author keywords

Colorectal carcinoma; Leukemia inhibitory factor receptor; Methylation

Indexed keywords

LEUKEMIA INHIBITORY FACTOR RECEPTOR; MESSENGER RNA;

ARTICLE; COLON CARCINOGENESIS; COLON MUCOSA; COLORECTAL CARCINOMA; CONTROLLED STUDY; DNA METHYLATION; HUMAN; HUMAN CELL; HUMAN TISSUE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION;

BASE SEQUENCE; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; DNA METHYLATION; DOWN-REGULATION; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HCT116 CELLS; HEK293 CELLS; HUMANS; MOLECULAR SEQUENCE DATA; PROMOTER REGIONS, GENETIC; RECEPTORS, OSM-LIF; TRANSCRIPTION, GENETIC;

EID: 79959959958     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2011.1050     Document Type: Article

References (36)

1. Jones PA and Baylin SB: The fundamental role of epigenetic events in cancer. Nat Rev Genet 3: 415-428, 2002. (Pubitemid 34587077)
2. Herman JG and Baylin SB: Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 349: 2042-2054, 2003. (Pubitemid 37448928)
3. Sidransky D: Emerging molecular markers of cancer. Nat Rev Cancer 2: 210-219, 2002.
4. Mandelker DL, Yamashita K, Tokumaru Y, et al: PGP9.5 promoter methylation is an independent prognostic factor for esophageal squamous cell carcinoma. Cancer Res 65: 4963-4968, 2005. (Pubitemid 40740837)
5. Belinsky SA, Nikula KJ, Palmisano WA, et al: Aberrant methylation of p16(INK4a) is an early event in lung cancer and a potential biomarker for early diagnosis. Proc Natl Acad Sci USA 95: 11891-11896, 1998.
6. Palmisano WA, Divine KK, Saccomanno G, et al: Predicting lung cancer by detecting aberrant promoter methylation in sputum. Cancer Res 60: 5954-5958, 2000.
7. Esteller M, Fraga MF, Guo M, et al: DNA methylation patterns in hereditary human cancers mimic sporadic tumorigenesis. Hum Mol Genet 10: 3001-3007, 2001. (Pubitemid 34083486)
8. Xu XL, Yu J, Zhang HJ, et al: Methylation profile of the promoter CpG islands of 31 genes that may contribute to colorectal carcinogenesis. World J Gastroenterol 10: 3441-3454, 2004. (Pubitemid 39549544)
9. Lind GE, Thorstensen L, Løvig T, et al: A CpG island hypermethylation profile of primary colorectal carcinomas and colon cancer cell lines. Mol Cancer 3: 28, 2004.
10. Auernhammer CJ and Melmed S: Leukemia-inhibitory factor-neuroimmune modulator of endocrine function. Endocr Rev 21: 313-345, 2000. (Pubitemid 32275591)
11. Yoshida K, Taga T, Saito M, et al: Targeted disruption of gp130, a common signal transducer for the interleukin 6 family of cytokines, leads to myocardial and hematological disorders. Proc Natl Acad Sci USA 93: 407-411, 1996. (Pubitemid 26041485)
12. Ware CB, Horowitz MC, Renshaw BR, et al: Targeted disruption of the low-affinity leukemia inhibitory factor receptor gene causes placental, skeletal, neural and metabolic defects and results in perinatal death. Development 121: 1283-1299, 1995.
13. Barasch J, Yang J, Ware CB, et al: Mesenchymal to epithelial conversion in rat metanephros is induced by LIF Cell 99: 377-386, 1999.
14. Bajaj P, Lawry J, Shenton G, et al: Interleukin-6 and tumour necrosis factor alpha synergistically block S-phase cell cycle and upregulate intercellular adhesion molecule-1 expression on MCF7 breast carcinoma cells. Cancer Lett 71: 143-149, 1993. (Pubitemid 23251986)
15. kip1 degradation in HepG2 cells. Oncogene 19: 3675-3683, 2000. (Pubitemid 30608489)
16. Nair BC, De Vico AL, Nakamura S, et al: Identification of a major growth factor for AIDS-Kaposi's sarcoma cells as oncostatin M. Science 255: 1430-1432, 1992.
17. Mosley B, De Imus C, Friend D, et al: Dual oncostatin M (OSM) receptors. Cloning and characterization of an alternative signaling subunit conferring OSM-specific receptor activation. J Biol Chem 271: 32635-32643, 1996. (Pubitemid 27008685)
18. Douglas AM, Goss GA, Sutherland RL, et al: Expression and function of members of the cytokine receptor superfamily on breast cancer cells. Oncogene 14: 661-669, 1997. (Pubitemid 27095857)
19. Tomida M: Structural and functional studies on the leukemia inhibitory factor receptor (LIF-R): gene and soluble form of LIF-R and cytoplasmic domain of LIF-R required for differentiation and growth arrest of myeloid leukemic cells. Leuk Lymphoma 37: 517-525, 2000.
20. Boccardo F, Rubagotti A, Conti G, et al: Prednisone plus gefitinib versus prednisone plus placebo in the treatment of hormone-refractory prostate cancer: a randomized phase II trial. Oncology 74: 223-228, 2008.
21. Grant SL, Douglas AM, Goss GA, et al: Oncostatin M and leukemia inhibitory factor regulate the growth of normal human breast epithelial cell. Growth Factors 19: 153-162, 2001. (Pubitemid 34065697)
22. Blanchard F, Kinzie E, Wang Y, et al: FR901228, an inhibitor of histone deacetylases, increases the cellular responsiveness to IL-6 type cytokines by enhancing the expression of receptor proteins. Oncogene 21: 6264-6277, 2002.
23. Blanchard F, Tracy E, Smith J, et al: DNA methylation controls the responsiveness of hepatoma cells to leukemia inhibitory factor. Hepatology 38: 1516-1528, 2003. (Pubitemid 37466978)
24. Loewen GM, Tracy E, Blanchard F, et al: Transformation of human bronchial epithelial cells alters responsiveness to inflammatory cytokines. BMC Cancer 5: 145, 2005.
25. Okamura Y, Nomoto S, Kanda M, Li Q, et al: Leukemia inhibitory factor receptor (LIFR) is detected as a novel suppressor gene of hepatocellular carcinoma using double-combination array. Cancer Lett 289: 170-177, 2010.
26. Kim MS, Louwagie J, Carvalho B, et al: Promoter DNA methylation of Oncostatin M receptor-β as a novel diagnostic and therapeutic marker in colon cancer. Plos One 4: e6555, 2009.
27. Kim MS, Chang X, Nagpal JK, et al: The N-methyl-D-aspartate receptor type 2A is frequently methylated in human colorectal carcinoma and suppresses cell growth. Oncogene 27: 2045-2054, 2008. (Pubitemid 351442740)
28. Kim MS, Yamashita K, Baek JH, et al: N-methyl-D-aspartate receptor type 2B is epigenetically inactivated and exhibits tumor-suppressive activity in human esophageal cancer. Cancer Res 66: 3409-3418, 2006.
29. Rockman SP, Demmler K, Roczo N, et al: Expression of interleukin-6, leukemia inhibitory factor and their receptors by colonic epithelium and pericryptal fibroblasts. J Gastroenterol Hepatol 16: 991-1000, 2001. (Pubitemid 32947141)
30. Jemal A, Murray T, Ward E, et al: Cancer statistics, 2005. CA Cancer J Clin 55: 10-30, 2005.
31. Toyota M, Ohe-Toyota M, Ahuja N, et al: Distinct genetic profiles in colorectal tumors with or without the CpG island methylator phenotype. Proc Natl Acad Sci USA 97: 710-715, 2000. (Pubitemid 30070374)
32. Kim MS, Chang X, Yamashita K, et al: Aberrant promoter methylation and tumor suppressive activity of the DFNA5 gene in colorectal carcinoma. Oncogene 27: 3624-3634, 2008. (Pubitemid 351793800)
33. Royuela M, Ricote M, Parsons MS, et al: Immunohistochemical analysis of the IL-6 family of cytokines and their receptors in benign, hyperplasic, and malignant human prostate. J Pathol 202: 41-49, 2004. (Pubitemid 38072844)
34. Gearing DP, Comeau MR, Friend DJ, et al: The IL-6 signal transducer, gp130: an oncostatin M receptor and affinity converter for the LIF receptor. Science 255: 1434-1437, 1992.
35. Underhill-Day N and Heath JK: Oncostatin M (OSM) cytostasis of breast tumor cells: characterization of an OSM receptor beta-specific kernel. Cancer Res 66: 10891-10901, 2006. (Pubitemid 44876987)
36. Wang Y, Robledo O, Kinzie E, et al: Receptor subunit-specific action of oncostatin M in hepatic cells and its modulation by leukemia inhibitory factor. J Biol Chem 275: 25273-25285, 2000.